Phoebe Lin
Retina Specialist · Cleveland, OHNPI 1952582785
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,073 of the $21,756 with a category attached, or 83.1%. Bausch & Lomb Americas Inc. accounts for 61.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $12,493 and has fallen 73.5% since, to $3,315 in 2025.
Across 43 payments — averaging $505.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$13K
- Regeneron$4K
- F. Hoffmann-la Roche AG$4K
- Genentech USA, Inc.$383
- Alimera Sciences, Inc.$190
- AbbVie$137
- plus $543 from 5 others
Across 23 payments — averaging $13,164 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche TCRC, Inc.$227K
- Genentech, Inc.$70K
- Astellas Pharma Global Development$4K
- F. Hoffmann-la Roche AG$1K
What the payments were for
- Consulting fees$18,07383%
- Speaking & faculty fees$4132%
- Travel & lodging$1,2036%
- Food & beverage$2,06810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 21 | $13,391 |
| Regeneron | 4 | $3,579 |
| F. Hoffmann-la Roche AG | 1 | $3,533 |
| Genentech USA, Inc. | 3 | $383 |
| Alimera Sciences, Inc. | 4 | $190 |
| AbbVie | 1 | $137 |
| Merz North America, Inc. | 4 | $134 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Eyepoint US, Inc. | 1 | $107 |
| Ocular Therapeutix, Inc. | 2 | $106 |
| Apellis Pharmaceuticals, Inc. | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,756 in reported general payments places this provider in the 75th percentile of 69 retina specialist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 65 | $4,519 |
| Prednisolone Acetate | 101 | $3,919 |
| Bromfenac Sodium | 17 | $2,948 |
| Mycophenolate Mofetil | 27 | $2,752 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 105 | $1,159 |
| ValacyclovirValacyclovir Hcl | 20 | $1,149 |
| Ketorolac Tromethamine | 65 | $1,121 |
| Brimonidine Tartrate | 65 | $788 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 57 | $513 |
| Latanoprost | 31 | $394 |
| Atropine Sulfate | 12 | $387 |
| Prednisone | 53 | $359 |
| Dorzolamide Hcl | 15 | $326 |
| Timolol Maleate | 15 | $114 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Cleveland
- Sumit SharmaCleveland$428K
- Aleksandra RachitskayaCleveland$303K
- Katherine TalcottCleveland$272K
- Suber HuangCleveland$124K
- Ananth SastryCleveland$44K
- Warren SobolCleveland$5K
- Mark SeralyCleveland$3K
- Abhishek NaiduCleveland$3K
- Mary-Grace ReevesCleveland$2K
- Joseph ConeyBeachwood$980K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.